Thrombolytic agents are plasminogen activators that convert plasminogen, the inactive
proenzyme of the fibrinolytic system in blood, to the proteolytic enzyme plasmin. Plasmin in …

Thrombotic complications of cardiovascular disease are a main cause of death and disability
and, consequently, thrombolysis could favorably influence the outcome of such life …

Streptokinase and urokinase have proved to be useful in a limited number of clinical
conditions. Mainly because of the risk and unpredictability of bleeding with this first …

Cardiovascular diseases, comprising acute myocardial infarction (AMI), stroke and venous
thromboembolism have, as their immediate underlying cause, thrombosis of critically …

Thrombolytic therapy of acute myocardial infarction is based on the premise that coronary
artery thrombosis is its proximate cause. Rupture of atheromatous plaque leads to occlusive …

Cardiovascular diseases comprise three main categories, namely coronary artery disease
leading to myocardial infarction or heart attacks, cerebrovascular disease causing strokes …

T hrombosis of a coronary or cerebral artery is the most common cause of mortality and
morbidity in the developed nations.'The proximate cause is most oftenatherosclerosis, and …

Thrombolysis today has become a routine option not only in the treatment of acute
myocardial infarction but also in many other manifestations of thromboembolic disease. Until …

All thrombolytic agents convert plasminogen to plasmin, either directly, as in the case of
urokinase, saruplase, and alteplase, or indirectly, as in the case of streptokinase. In the …

In the past 10 years, thrombolytics have become standard therapy for acute myocardial
infarction. Although the ability of streptokinase to lyse clot was first recognised in the 1930s …